Floatz logo

Pegylated-Interferon .Alfa. 2B (Peg-Ifn)

Fibrotic Liver Disease

Third Affiliated Hospital, Sun Yat-Sen Universityprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Fibrotic Liver Disease cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
Colchicinum
Zagazig University
Phase 4BB
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Pegylated-Interferon .Alfa. 2B (Peg-Ifn) is also rated in:

chronic hepatitis C virus infectionDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
hepatitis C virus infectionDormant
BB
Indicative · Phase 4
70 / 100
View asset →
cirrhosis of liverActive
B
Indicative · Phase 3
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →